Ipca Laboratories profit and loss

Latest FY26

Revenue: ₹9,646cr+7.9% on FY25
EBITDA: ₹1,979cr+14.6% on FY25
Net profit: ₹1,184cr+50.8% on FY25
EPS: ₹44.98+54.7% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	10,126	9,646	8,940	7,705	6,244	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	167	174	92.8	125	126
	10,293	9,821	9,032	7,830	6,370
	2,365	2,344	2,277	2,216	1,709
	547	533	548	490	497
	16.9	−53.9	−46.1	−131	101
	2,219	2,160	1,984	1,708	1,288
	69.3	75.9	84.9	138	45.5
	429	418	398	357	262
	2,747	2,685	2,451	2,100	1,723
	8,392	8,162	7,696	6,879	5,625
	2,232	1,979	1,726	1,321	927
	1,803	1,560	1,328	964	665
Profit
	1,901	1,659	1,336	950	745
	−86.4	−86.4	−205	−108	0.0
	1,814	1,573	1,131	843	745
	455	418	372	310	230
	−20.6	−36.7	−28.4	3.3	23.0
	434	381	344	313	253
	−4.6	−7.6	−2.3	−6.3	−12.9
	1,375	1,184	785	523	479
	1,380	1,191	788	529	492
	17.7	42.8	−24.6	−9.5	7.3
	1,393	1,227	761	513	486
	1,310	1,141	738	547	471
	65.4	42.7	47.6	−24.4	7.7
Per share
	₹51.63	₹44.98	₹29.08	₹21.57	₹18.58
	₹51.63	₹44.98	₹29.08	₹21.57	₹18.58
Other comprehensive income — detail
	17.7	42.8	−24.6	—	—
	−4.3	16.1	−5.1	−8.8	−2.4
	−0.0	3.8	−1.9	—	—
	—	—	—	−0.6	−0.6
	22.6	30.9	−22.1	−1.3	8.8
	0.6	0.5	−0.7	—	—
	—	—	—	−0.0	−0.4
	1,325	1,178	717	539	479
	68.1	48.3	44.0	−25.8	7.7
Per share — as-filed variants
	₹51.63	₹44.98	₹29.08	₹21.57	₹18.58
	₹51.63	₹44.98	₹29.08	₹21.57	₹18.58
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	7,197	6,824	6,161	5,129	3,938
	71.1%	70.7%	68.9%	66.6%	63.1%
Adjusted (ex-exceptional items) — derived
	1,901	1,659	1,336	950	745
	−86.4	−86.4	−205	−108	0.0
	1,441	1,249	928	591	479
	₹54.10	₹47.47	₹34.37	₹24.36	₹18.58

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

IPCALAB₹1,930.50

Ipca Laboratories Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersTORNTPHARM ALKEM JBCHEPHARM ABBOTINDIA AJANTPHARM ANTHEM GLAXO MEDANTAMcap ₹48,977 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	6,244.3	7,705.0	8,939.6	9,646.3	10,125.6
Other Income	125.6	124.8	92.8	174.5	167.1
Total Income	6,369.9	7,829.8	9,032.4	9,820.8	10,292.6
Expenses
+ Cost of Materials Consumed	1,708.7	2,216.3	2,276.8	2,344.0	2,365.1
+ Purchases of Stock-in-Trade	497.2	490.1	547.8	532.6	546.6
+ Changes in Inventories	100.7	-130.6	-46.1	-53.9	16.9
+ Employee Benefit Expense	1,287.6	1,708.4	1,984.0	2,160.2	2,218.6
+ Finance Costs	45.5	138.3	84.9	75.9	69.3
+ Depreciation & Amortisation	261.6	357.2	397.8	418.1	428.9
+ Other Expenses	1,723.4	2,099.7	2,450.9	2,684.9	2,746.8
Total Expenses	5,624.7	6,879.4	7,696.2	8,161.8	8,392.1
EBITDA	926.8	1,321.2	1,726.1	1,978.6	2,231.7
EBIT	665.2	963.9	1,328.3	1,560.4	1,802.8
Profit
PBT before Exceptional Items	745.3	950.4	1,336.2	1,659.0	1,900.5
+ Exceptional Items	0.0	-107.8	-205.1	-86.4	-86.4
Pretax Income	745.3	842.7	1,131.1	1,572.5	1,814.1
+ Current Tax	230.4	310.2	372.1	417.8	455.0
+ Deferred Tax	23.0	3.3	-28.4	-36.7	-20.6
Tax Expense	253.4	313.5	343.6	381.2	434.3
+ Share of Associates & JVs	-12.9	-6.3	-2.3	-7.6	-4.6
Net Income	479.0	522.9	785.2	1,183.8	1,375.2
+ Net Income — Continuing Ops	491.9	529.2	787.5	1,191.4	1,379.8
+ Other Comprehensive Income	7.3	-9.5	-24.6	42.8	17.7
Total Comprehensive Income	486.3	513.5	760.7	1,226.5	1,392.9
Net Income to Common	471.3	547.4	737.7	1,141.1	1,309.8
Minority Interest	7.7	-24.4	47.6	42.7	65.4
Per Share
Basic EPS	18.58	21.57	29.08	44.98	51.63
Diluted EPS	18.58	21.57	29.08	44.98	51.63
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-24.6	42.8	17.7
+ Items NOT to be Reclassified to P&L	-2.4	-8.8	-5.1	16.1	-4.3
+ Tax on Items NOT to be Reclassified	—	—	-1.9	3.8	-0.0
+ Tax on Items NOT to be Reclassified — alt tag	-0.6	-0.6	—	—	—
+ Items to be Reclassified to P&L	8.8	-1.3	-22.1	30.9	22.6
+ Tax on Items to be Reclassified	—	—	-0.7	0.5	0.6
+ Tax on Items to be Reclassified — alt tag	-0.4	-0.0	—	—	—
Comprehensive Income — Owners of Parent	478.7	539.3	716.7	1,178.2	1,324.8
Comprehensive Income — Non-controlling Interests	7.7	-25.8	44.0	48.3	68.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	18.58	21.57	29.08	44.98	51.63
Diluted EPS — Continuing Operations	18.58	21.57	29.08	44.98	51.63
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	3,937.8	5,129.3	6,161.0	6,823.6	7,197.1
Gross Margin %	63.06	66.57	68.92	70.74	71.08
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	745.3	950.4	1,336.2	1,659.0	1,900.5
− Exceptional Items (reconciliation)	0.0	-107.8	-205.1	-86.4	-86.4
Net Income Adj (tax-effected)	479.0	590.6	928.0	1,249.3	1,440.9
EPS Adj	18.58	24.36	34.37	47.47	54.10
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	25.4	25.4	25.4	25.4	25.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.